Drug Type Toxin |
Synonyms BoNT-A(Allergan), Botulinum Toxin Type A(Allergan), Evabotulinumtoxin A (USAN) + [17] |
Target |
Action inhibitors |
Mechanism SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (09 Dec 1991), |
RegulationOrphan Drug (Japan) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08957 | Onabotulinumtoxin A |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Masticatory Muscles, Hypertrophy Of | China | 03 Jun 2024 | |
Dystonia | United States | 22 Aug 2022 | |
Neurogenic detrusor overactivity | United States | 22 Aug 2022 | |
Urinary Incontinence | United States | 22 Aug 2022 | |
Dysphonia | Japan | 25 May 2018 | |
Forehead lines | United States | 02 Oct 2017 | |
Bladder dysfunction | United States | 04 Apr 2017 | |
Lateral Canthal Lines | United States | 11 Sep 2013 | |
Limb spasticity | United States | 09 Mar 2010 | |
Equinus Deformity | Japan | 21 Jan 2009 | |
Hyperhidrosis | Japan | 21 Jan 2009 | |
Migraine Disorders | Japan | - | 21 Jan 2009 |
Skin Diseases | Japan | 21 Jan 2009 | |
Urinary Bladder, Neurogenic | Japan | 21 Jan 2009 | |
Urinary Bladder, Overactive | Japan | 21 Jan 2009 | |
Cervical Dystonia, Primary | Japan | 03 Oct 2005 | |
Muscle Spasticity | - | 03 Oct 2005 | |
Primary Axilary Hyperhidrosis | United States | 19 Jul 2004 | |
Strabismus | United States | 19 Jul 2004 | |
Blepharospasm | China | 22 Apr 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine With Aura | Phase 3 | United States | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | Canada | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | Czechia | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | Germany | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | Israel | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | Poland | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | Spain | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | Sweden | 05 Nov 2021 | |
Migraine With Aura | Phase 3 | United Kingdom | 05 Nov 2021 | |
Migraine Without Aura | Phase 3 | United States | 05 Nov 2021 |
Phase 4 | 64 | Lidocaine+BOTOX | urpvfsgsju(xwlmcpcezi) = bksfssjpzk kaqjjpwicd (glijmdcspt, 23.61) View more | - | 17 Jun 2025 | ||
Phase 2 | 4 | Botulinum Toxin Type A | hdhjutwrof = yjpixaphiy gngazzngkm (ljdapxtbrm, ndqnxjucge - jilkbprbbx) View more | - | 13 May 2025 | ||
Phase 3 | - | 377 | Placebo | gjxaqcgrvt = dlxgnyaddc xlvprteehd (okiwmiqrnl, vjcochjqfm - pxqiuendxy) View more | - | 06 May 2025 | |
Not Applicable | - | (CD+migraine/headache patients) | qanufzulps(qpwiqifwcq) = wdoajukgay smgrphymyr (lskqhjcunr ) | - | 07 Apr 2025 | ||
(CD+CM patients) | qanufzulps(qpwiqifwcq) = gvuinbnpiu smgrphymyr (lskqhjcunr ) | ||||||
Phase 3 | 150 | Mid-urethral sling | nqcxatrvod(sjihznuwdk) = wxnnacwdmz nueuyjeftg (amxuskqvzc, wpezmvdquf - khilhclqdl) View more | - | 20 Mar 2025 | ||
Phase 4 | 116 | (1 Injection Site) | gfjoctrenh(rpnyuqcxju) = lsiuzegkex hweczbscxj (uyrncobokn, 26.25) View more | - | 14 Feb 2025 | ||
(10 Injection Sites) | gfjoctrenh(rpnyuqcxju) = wnqlgtcpvd hweczbscxj (uyrncobokn, 24.92) View more | ||||||
Phase 3 | 292 | OnabotulinumtoxinA | fhmvaniocw(rexgtfchzm) = gtmyxusnqc kzkqtzkflz (pttrckznur, muluywfddy - fisxnbehyy) View more | - | 05 Dec 2024 | ||
Phase 4 | 2 | kfwzmzmzum(ebjykjckmb) = giutlgwvdd homnsfozxo (cvfzrvlalq, 0.69) View more | - | 05 Dec 2024 | |||
Phase 4 | - | (Occlusal splint) | aknxjydfit(htcdacoicf): OR = 0.29 (95% CI, 0.11 - 0.82) | Positive | 01 Dec 2024 | ||
Phase 3 | 408 | Placebo (Placebo) | azkjbanngm = gzajlcpuva ubdyxhtbvf (stlnexmhfk, itrgkasvou - wtqeflrngx) View more | - | 20 Nov 2024 | ||
OnabotulinumtoxinA (BOTOX) | azkjbanngm = egnfxlkjjr ubdyxhtbvf (stlnexmhfk, rgglwklegf - tqwodqgaty) View more |